Alterations in gap junction protein expression in human benign prostatic hyperplasia and prostate cancer

被引:16
|
作者
Habermann, H
Ray, V
Habermann, W
Prins, GS
机构
[1] Univ Illinois, Dept Urol, Chicago, IL 60612 USA
[2] Provident Hosp, Dept Pathol, Chicago, IL USA
[3] Graz Univ, Dept Urol, Graz, Austria
[4] Graz Univ, Dept Otorhinolaryngol Head & Neck Surg, Graz, Austria
来源
JOURNAL OF UROLOGY | 2001年 / 166卷 / 06期
关键词
prostate; prostatic neoplasms; prostatic hyperplasia; GTPase-activating proteins; connexins;
D O I
10.1016/S0022-5347(05)65548-6
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Gap junctions composed of connexin proteins have an essential role in intercellular communication and differentiation. Dysregulation of connexin expression is believed to have a role in carcinogenesis. The human prostate has been reported to express connexin 32 and 43. However, the expression pattern in prostate cancer is controversial, while to our knowledge connexin expression has not been reported in benign prostatic hyperplasia (BPH). To understand the potential involvement in prostate disease connexin 32 and 43 expression was evaluated in a series of normal prostate, BPH and prostate cancer specimens that were surgically removed due to bladder outlet obstruction. Materials and Methods: Frozen sections of 23 normal, 43 BPH and 40 cancer involved prostates were evaluated for the presence, staining intensity and pattern of connexin 32 and 43 by immunocytochemical testing. Results: In all specimens examined connexin 43 stain was punctate along the borders of the basal epithelial cells, whereas connexin 32 immunolocalized to luminal epithelial cells: In normal prostate connexin 43 and 32 were present in 87% and 65% of specimens, respectively, at low to moderate stain intensity. Importantly none of the normal samples were negative for each connexin. In BPH specimens there was a marked increase in the incidence and intensity of connexin 43 and 32 immunostaining within epithelial cells. In addition, 23% of BPH samples showed strong connexin 43 expression in stromal cells. In contrast, connexin was decreased in prostate cancer specimens, of which 65% and 38% were negative for connexin 43 and 32, respectively, and 28% were negative for each type. In poorly differentiated tumors connexin 43 and 32 were present in only 10% and 40% of tumors, respectively, at low immunostaining intensity. Conclusions: In normal human prostate basal cells communicate via connexin 43 gap junctions, whereas luminal cells communicate via connexin 32 gap junctions. In BPH gap junctional intercellular communication is increased in epithelial and stromal cells, which may have a role in BPH pathogenesis. In prostate cancer gap junctional intercellular communication is decreased, is as indicated by decreased expression of connexin 43 and 32 with severe loss in poorly differentiated prostate cancer. These alterations in connexin expression may have a role in dedifferentiation and tumor progression.
引用
收藏
页码:2267 / 2272
页数:6
相关论文
共 50 条
  • [1] Alterations in gap junction protein expression in human benign prostatic hyperplasia and prostate cancer (vol 166, pg 2269, 2001)
    Habermann, H
    Ray, V
    Habermann, W
    Prins, GS
    JOURNAL OF UROLOGY, 2002, 167 (02): : 655 - 660
  • [2] Osteopontin expression in prostate cancer and benign prostatic hyperplasia
    Tozawa, K
    Yamada, Y
    Kawai, N
    Okamura, T
    Ueda, K
    Kohri, K
    UROLOGIA INTERNATIONALIS, 1999, 62 (03) : 155 - 158
  • [3] Expression of the KAl1 protein in benign prostatic hyperplasia and prostate cancer
    Ueda, T
    Ichikawa, T
    Tamaru, J
    Mikata, A
    Akakura, K
    Akimoto, S
    Imai, T
    Yoshie, O
    Shiraishi, T
    Yatani, R
    Ito, H
    Shimazaki, J
    AMERICAN JOURNAL OF PATHOLOGY, 1996, 149 (05): : 1435 - 1440
  • [4] Junction plakoglobin gene polymorphisms in prostate cancer and benign prostatic hyperplasia
    Liu, Jan
    Chang, Inik
    Singh, Kamaldeep
    Dahiya, Angela V.
    Majid, Shahana
    Saini, Sharanjot
    Zaman, Mohd S.
    Chen, Yi
    Shahryari, Varahram
    Sandhu, Herman
    Yamamura, Soichiro
    Suh, Seong O.
    Deng, Guoren
    Tanaka, Yuichiro
    CANCER RESEARCH, 2011, 71
  • [5] Androgen Receptor Expression In Benign Prostatic Hyperplasia And Prostate Cancer
    Putriyuni, Anandia
    Liana, Nana
    JOURNAL OF POPULATION THERAPEUTICS AND CLINICAL PHARMACOLOGY, 2023, 30 (05): : E430 - E436
  • [6] Benign prostatic hyperplasia, prostate cancer
    Lebdai, S.
    PROGRES EN UROLOGIE, 2017, 27 (03): : F60 - F62
  • [7] Benign prostatic hyperplasia, prostate cancer
    Mathieu, R.
    PROGRES EN UROLOGIE, 2015, 25 : F82 - F84
  • [8] Benign prostatic hyperplasia, prostate cancer
    Mathieu, R.
    PROGRES EN UROLOGIE, 2016, 26 (01): : F20 - F22
  • [9] BENIGN PROSTATIC HYPERPLASIA AND CANCER OF PROSTATE
    BYAR, DP
    LANCET, 1975, 1 (7911): : 866 - 866
  • [10] Benign prostatic hyperplasia, cancer of the prostate
    Lebdai, S.
    PROGRES EN UROLOGIE, 2017, 27 (02): : F40 - F42